Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors - Wikidata - wikimedia - TriplyDB

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

http://www.wikidata.org/entity/Q28258745

about

The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2)Novel extrapancreatic effects of incretin Pancreatic regulation of glucose homeostasis Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes GLP-1-based strategies: a physiological analysis of differential mode of action DPP-4 inhibition and islet function Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor Anchored phosphatases modulate glucose homeostasis Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.Lipotoxicity disrupts incretin-regulated human β cell connectivity Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.GIP and GLP-1, the two incretin hormones: Similarities and differences Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival.Emerging gliptins for type 2 diabetes.Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.The role of incretins in glucose homeostasis and diabetes treatment.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control.Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.Mice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity.Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities Investigating endogenous peptides and peptidases using peptidomics Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery.The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.The GLP-1 system as a therapeutic target.Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.Biologic actions and therapeutic potential of the proglucagon-derived peptides.Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice

P2860

Q24656123-D0E80ECD-A41E-4F41-BFD6-1F3EC6348EC9 Q26749181-07C71F57-7DDC-4248-BD94-D0452FE25D36 Q26766485-6E6014FE-C988-4148-AFCA-967C6D21C119 Q26785454-41066FE4-5A71-459D-9319-17560C5DB09C Q26997149-E8CB077D-9505-44A7-81B4-8898F6172EC4 Q27028127-8E1F76E7-AD72-4BDF-B7EE-2CB4325C42AB Q27678197-C1DC6F36-29F1-4B36-881B-1FCC23C067A9 Q28507313-2B8626BB-6A05-4AE9-B52A-8D60A79FE6F3 Q30478488-CBF8AA2D-B740-4E98-B877-A6599210004A Q30634760-806AD7BF-5064-4359-BDD8-210260EF4BE3 Q33602360-C1A9BCA8-0AC5-49A4-AFE1-33FD75EB4206 Q33603384-E4E07F87-C204-47DB-82BC-8735F2853E64 Q33609502-22B70764-56A7-42D9-8C23-49044E474223 Q33815664-ACEA3DC0-1315-4AC9-9602-DB7BB26C62FB Q34347884-7B4F029D-25D2-4982-ABD3-FBF4B2C741D8 Q34519292-B6F81A3D-6EAD-48B5-B183-9219DC4FC5CC Q34620636-A5F8FA3C-CB6D-444F-998E-020D92CC4580 Q34888374-261F39E9-583D-413C-9215-471F25367CB6 Q34901533-AF2A2E23-7301-4CF9-A68D-B206924694B7 Q34963221-2DDBEC4E-B8AB-4717-895D-CC8FC14CC3DC Q35138670-909839B6-5FE6-4B2B-869B-89899711BDCA Q35532241-8C37FC88-F82E-428C-BD61-DB746CCFB945 Q35640531-73CFBB9D-E89E-4CBC-9419-7DFAACA38E10 Q35778163-CF0F97E6-6FA8-4A3A-BE99-2C7B0B32BCEC Q35871904-BD381286-5693-44E9-B2E1-94429095008D Q36040879-E97B9486-4570-4CF7-868B-A54E718E209C Q36153247-1780EA49-4923-48A9-8C4C-554959B2B01A Q36163374-CA1F82CF-60B2-4DF1-8357-B6900F22D738 Q36175901-D67E8C5D-A0DF-48B8-BDD6-A1867B6FAA42 Q36187070-B0D4BD17-90C9-481F-A61C-E53F73D3BBE4 Q36265221-E3C44529-6433-4CF9-84BB-1C54B864FE7D Q36477333-B13EC089-7452-4CA2-BD16-DA564CEC56B9 Q36560559-AF553682-A1CE-408B-A602-1C26C2566443 Q36575421-A3FD9525-8C09-46CD-9C7A-48E5673935EB Q36735761-77397ECC-7361-437E-8314-DAD95A0FBD8F Q36971308-0AA714D2-C995-4B7A-AA5D-1B0E15B52A07 Q36990110-98E298AC-9E6F-485E-90C4-4F82E0E05A27 Q37175498-088CAFC7-44CE-4A65-BA9F-9497D4E5F6EB Q37193295-EAE0A5FE-BD3E-49B7-8C4C-B440A2017487 Q37240144-DE5F5272-FE7C-4FB5-A1E9-D71AC9468B82

P2860

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

http://www.wikidata.org/entity/Q28258745

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@ast

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@en

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@nl

type

label

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@ast

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@en

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@nl

prefLabel

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@ast

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@en

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@nl

P1433

Q28258745-C1932CFF-5584-4BD7-81F1-A3A2EBC03C92

P1476

Q28258745-B56782B7-004F-4495-8053-1CAA3EE071BC

P2093

Q28258745-181B41DA-B69F-4D87-8CDD-9F71256F5E8A

Q28258745-47410E90-5A83-4771-96E1-0C01ECC12953

Q28258745-5351D730-2538-4063-A43F-9A3A1F0673B5

Q28258745-661B5E31-770E-4B3A-AFED-1B12633E58ED

Q28258745-68124E83-F6DB-46F8-848A-8AF6E5B16376

Q28258745-BC8BC64E-F255-45F0-AA2A-9045C50CF3E0

Q28258745-DAADFD0A-DEF5-4021-B48A-170F74BDFC93

Q28258745-F5824510-7F32-4FAE-A496-7616EAACD9AA

P304

Q28258745-725E6D60-41CF-43F5-B902-D962F86406AC

P31

Q28258745-B36E9139-2F6C-4ECF-BE5B-764771BC14A1

P3181

Q28258745-31273F91-6AFD-473B-A133-54209BDD2023

P356

Q28258745-62B89835-B876-4544-BCFB-BE3330E038E6

P407

Q28258745-C22CF143-4D7E-4956-B75B-7381B1E2F2AE

P433

Q28258745-3857A736-D74A-4DDA-8AA6-535A4A98C658

P478

Q28258745-13A55E45-6087-472C-B10A-8F3EA064FFD7

P50

Q28258745-EFAA4138-730B-4420-A996-C9721D09A601

Q28258745-bcc8b6c1-4507-a8cf-c9aa-902e2d936bb2

P577

Q28258745-47252C85-9A59-4D9F-99D3-EBD375ECDBFF

P5875

Q28258745-865D414D-2EF3-4D20-8527-175F2C5D45B1

P698

Q28258745-C9F7D5AB-F528-4072-AC3C-EA6EF778DAB7

P3181

P356

DIABETES.53.5.1326

P1433

P1476

Double incretin receptor knock ...... y actions of DPP-IV inhibitors

@en

P2093

D J Drucker

http://www.w3.org/2001/XMLSchema#string

Dominique Delmeire

http://www.w3.org/2001/XMLSchema#string

Katsushi Tsukiyama

http://www.w3.org/2001/XMLSchema#string

Laurie L Baggio

http://www.w3.org/2001/XMLSchema#string

Simon A Hinke

http://www.w3.org/2001/XMLSchema#string

Tanya Hansotia

http://www.w3.org/2001/XMLSchema#string

Yuichiro Yamada

http://www.w3.org/2001/XMLSchema#string

Yutaka Seino

http://www.w3.org/2001/XMLSchema#string

P304

1326-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2454199

http://www.w3.org/2001/XMLSchema#string

P356

10.2337/DIABETES.53.5.1326

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8592732

http://www.w3.org/2001/XMLSchema#string

P698

15111503

http://www.w3.org/2001/XMLSchema#string